Systematic review with meta-analysis on transplantation for alcohol-related liver disease: Very low evidence of improved outcomes

Table 1 Details of included studies and cohort baseline characteristics

Study	Place	Study design	Transplant					No-transplant
			n (%)	Age1 (SD or range)	Male sex n (%)	CTP1 (SD or range)	MELD (SD or range)	n (%)	Age1 (SD or range)	Male sex n (%)	CTP1 (SD or range)	MELD (SD or range)
Gish et al[24]	United States	P, C	29 (62)	472	30 (64)2	12 (9-15)2		14 (30)	472	30 (64)2	13 (9-15)2
Anand et al [22]	United Kingdom	R, C	39 (28)	48 (37-69)	34 (87)	113		94 (69)	51 (30-71)3	67 (74)	113
Poynard et al [25]	France	R, CC	169 (50)	47 (39-55)	NS	9 (5-15)3		169 (50)	47 (39-54)	NS	9 (5-15)3
Veldt et al[26]	France	P, C	2 (3)	59 (37-82)2	47 (64)2	11 (10-15)2		72 (97)	59 (37-82)2	47 (64)2	11 (10-15)2
DiMartino et al[23]	France	P, RCT	60 (50)	502	92 (77)2	8.22		60 (50)	502	92 (77)2	8.22
Immordino et al[20]	Germany	R, C	110 (45)	53 (30-68)	95 (86)	10 (6-13)	14 (4-35)	113 (46)	50 (33-64)	64 (57)	6.5 (5-13)	12 (6-40)
Alvarez et al [21]	Spain	P, C	5 (3)	< 65	NS	> 8	14 (13-15)2	156 (95)	56 (54-58)2	135 (82)2	9 (8-9)2	14 (13-15)2
Mathurin et al[18]	France	P, CC	26 (27)	47 (35-61)	15 (58)	NS	30 (22-47)	69 (73)	52 (47-54)	41 (59)	NS	NS
Im et al[19]	United States	P, CC	9 (10)	41 (30-60)	5 (55)	NS	39 (27-42)	79 (84)	48 (26-68)2	54 (57)2	NS	31 (16-52)2
Onishi et al[27]	Japan	R,	7 (7)	44 (28-51)	4 (57)	10.1(2)2	NS4	50 (75)	52 (31-69)	37 (74)	10.1 (2)2	NS4

¹Median values used if both mean and median were reported;

²Value is for the entire study population (both transplant and no-transplant);

³Calculated as the weighted average;

⁴Mean model for end-stage liver disease reported as 1.9 for the entire study population was omitted given concern for publication error.

P: Prospective; R: Retrospective; C: Cohort; CC: Case-control; RCT: Randomized controlled trial; CTP: Child-Turcotte-Pugh score; MELD: Model for end-stage liver disease; NS: Not specified.

Table 2 Weighted average of baseline characteristics

	n (%)	Male n (%)	Age	CTP	MELD
Transplant	456 (34.2)	153 (80.1)	46.7	9.8	18.4
No-transplant	876 (65.8)	183 (64.1)	49.6	8.7	15.21

¹Used data from 26 matched controls of Mathurin et al[18] trial to calculate weighted average as data for all 69 of the entire cohort was not available. CTP: Child-Turcotte-Pugh score; MELD: Model for end-stage liver disease.

Table 3 Outcomes of included studies

Study	Transplant					No-transplant
	Abstinence length (SD or range)1	Relapse n (%)	Mortality n (%)	Loss to follow-up n (%)	Follow-up length (SD or range)1	Abstinence length (SD or range)1	Relapse n (%)	Mortality n (%)	Loss to follow-up n (%)	Follow-up length (SD or range)1
Gish et al[24]	21	6 (21)	2 (7)	0 (0)	24 (12-41)2	5	13 (93)	8 (57)	5 (36)	24 (12-41)2
Anand et al[22]	18 (6-130)	5 (13)	9 (23)	0 (0)	25 (7-63)	11 (2-86)3	27 (37)	48 (51)	11 (12)	24 (6-90)
Poynard et al[25]	≥ 64	31 (18)	56 (33)	0 (0)	28 (21-37)	NS	NS	71 (42)	NS	NS
Veldt et al[26]	≥ 6	NS	NS	NS	NS	NS	NS	NS	NS	NS
DiMartino et al[23]	NS	4 (6)	NS	NS	422	NS	13 (21)	NS	NS	422
Immordino et al[20]	NS	13 (12)5	40 (36)	NS	120	NS	5 (6)	18 (18)	14 (12)	120
Alvarez et al[21]	NS	NS	116 (70)2	9 (5)2	54 (19-96)2	NS	NS	116 (70)2	9 (5)2	54 (19-96)2
Mathurin et al[18]	NS	3 (12)	6 (23)	NS	24	NS	NS	48 (70)	NS	24
Im et al[19]	NS	2 (22)	1 (11)	NS	25 (6-39)	NS	NS	65 (76)6	NS	NS
Onishi et al[27]	21.2 (17.4)7	1 (14)	NS	NS	61.2	8.8 (13.6)	NS	NS	NS	NS

¹Median values used if both mean and median were reported and length was reported in months;

²Value is for the entire study population (both transplant and no-transplant);

³Calculated as the weighted average;

⁴All of the patients were abstinent for greater than 6 mo prior to transplant with the exception of one patient;

⁵Only 1 patient of the 8 with acute alcohol-related hepatitis relapsed;

⁶Includes 6 patients on the transplant waiting list;

⁷Includes transplant and waitlist patients. SD: Standard deviation; NS: Not specified.